Understanding⁤ RSV: A ‍Threat across the Lifespan

Respiratory Syncytial virus (RSV) is a common respiratory virus that ⁣usually causes mild, cold-like symptoms. However,for infants,young children,and older adults,RSV can lead to severe ⁣illness,including bronchiolitis and pneumonia. Before the advent of these vaccines, RSV was responsible for an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually in the ⁤United States among ‍older adults, and a significant number of hospitalizations⁢ in young children.

The virus spreads through respiratory droplets produced when an infected person coughs or‍ sneezes. ‍ Symptoms typically⁣ appear 4-6 days after infection and include a runny nose, decreased appetite, cough,⁣ sneezing, fever, and wheezing. While most people recover within a week or two,severe cases require hospitalization and supportive care.

The Vaccines: A Two-Pronged Approach

In May 2023, the Food and drug Administration (FDA) approved two distinct RSV ⁣vaccines, marking a ‍pivotal moment in the fight against this pervasive ⁤virus. These vaccines target different populations with tailored approaches:

• Arexvy (GSK): Approved for adults aged 60 years and older. This vaccine utilizes a recombinant subunit vaccine technology,presenting a stabilized prefusion F protein to elicit an immune response.
• abrysvo (pfizer): Approved for both older adults (60 years and older) and for use in pregnant individuals to protect their infants. For pregnant people, the vaccine⁢ is administered between 32 and 36 weeks of gestation, allowing antibodies to transfer to the baby, providing early protection.

Data published in the New England Journal of⁤ Medicine on october 9, 2025, continues to demonstrate the efficacy of both vaccines. Studies show ⁣that Arexvy provides approximately 82.6% efficacy against RSV-associated lower respiratory ⁣tract disease (LRTD) in older adults, ‍with protection lasting at least one⁣ season. Abrysvo demonstrated similar efficacy in older adults ⁣and, crucially, a 77.3% efficacy⁤ in preventing medically attended RSV infection in⁤ infants born to vaccinated mothers.

Clinical Trial⁣ Results: A Deeper Dive

The clinical trials leading to the approval of these vaccines ⁢were rigorously designed and conducted. The trials for Arexvy involved‍ over 25,000 adults aged 60 ⁢years and older. ⁣ ‍The primary endpoint was RSV-associated LRTD, and the vaccine consistently demonstrated significant efficacy. Similarly,the trials ‍for Abrysvo,including the maternal vaccination component,enrolled thousands of pregnant ⁤individuals and their infants,showcasing the‍ vaccine’s ability to protect newborns.